EXAS Technical Analysis & Stock Price Forecast
The article provides a technical analysis for Exact Sciences Corp (EXAS), indicating a "Strong Buy" overall consensus based on aggregated technical signals. It details various indicators like RSI, MACD, and moving averages, along with key support and resistance levels. Despite some sell signals from momentum oscillators like RSI and Stochastic, the stock is trading above its key moving averages, suggesting a bullish trend.
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now
Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively for long-term growth.
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now
Abbott Laboratories completed its $23 billion acquisition of Exact Sciences on March 23, 2026, integrating Exact Sciences' cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics division. This acquisition positions Abbott in the growing $60 billion U.S. cancer screening market, offering North American investors exposure to diversified revenue and reduced single-product risk. Analysts view the deal positively, expecting it to be accretive long-term despite near-term EPS dilution, with upcoming Q1 2026 earnings acting as a key checkpoint for integration and growth.
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026?
Exact Sciences stock has seen a post-earnings slide, but the company's core Cologuard franchise continues to grow, and profitability is becoming clearer. The article examines the fundamental changes, Wall Street's sentiment, and how US investors might position themselves for 2026. It highlights the company's strong revenue growth, improving margins, and robust cash position, despite ongoing unprofitability on a GAAP basis, making it a risk-reward test for high-growth healthcare investors.
Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History
This article from GuruFocus.com, titled "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History," provides historical holding information for Exact Sciences Corp (EXAS) within the Select Health Care Portfolio. The content is primarily a navigation-heavy page from a financial data website, indicating where users can find such data and related investment tools. It does not provide direct analysis or details of the holding history itself, but rather signposts the availability of such information on the platform.
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
EXACT Sciences Corp., a Pharmaceuticals & Biotechnology company, has received a mixed stock evaluation with varying technical indicators. Despite this, the company has significantly outperformed the S&P 500 over both the past year and decade, demonstrating strong resilience and stock performance recovery. Key technical indicators show both bullish and bearish signals across different timeframes.
Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares
The Vanguard Group has reported 0 shares of Exact Sciences (NASDAQ: EXAS) common stock, representing 0% ownership, following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing emphasizes that this reclassification is a reporting change, not an indication of a sale.
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update
Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks like competition and potential reimbursement cuts remain.
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update
Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seeking exposure to this sector, though competition and regulatory risks remain.
Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist
Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.
Abbott completes Exact Sciences acquisition
Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.
Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026
Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and drive future development of preventative and personalized diagnostic tools.
Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing
Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.
Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges
Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a "Moderate Buy" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Switzerland and the alignment with precision medicine trends.
The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout
Walgreens has partnered with Exact Sciences for a nationwide rollout of the Cologuard colorectal cancer screening test through its pharmacies, which could significantly impact Exact Sciences' growth. While this expansion addresses care gaps and diversifies screening access, investors should also consider Exact Sciences' historical cash burn and dependence on Cologuard, despite new data on its Oncodetect and Cancerguard tests. The company's investment narrative projects substantial revenue and earnings growth by 2028, with fair value estimates aligning with or exceeding its current price.
Exact Sciences (NASDAQ: EXAS) secures approvals as Abbott merger targets March 23 close
Exact Sciences has announced that all regulatory approvals and clearances for its merger with Abbott Laboratories have been obtained. Stockholders previously approved the transaction on February 20, 2026, and the merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions. Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.
Abbott to close $21B Exact Sciences acquisition Monday
Abbott is set to finalize its $21 billion acquisition of Exact Sciences on Monday, having received all necessary regulatory clearances. This strategic move is expected to significantly bolster Abbott's presence in cancer screening and diagnostics, adding a new platform and an estimated $3 billion in incremental sales by 2026. Exact Sciences is known for its Cologuard test and other molecular cancer detection technologies, which Abbott anticipates will help reach millions more people for early cancer detection and management.
Exact Sciences to be acquired by Abbott after receiving all regulatory approvals; closing anticipated March 23, 2026
Exact Sciences announced that all regulatory approvals for its merger with Abbott have been received, with the transaction expected to close on March 23, 2026. This merger will make Exact Sciences a direct, wholly owned subsidiary of Abbott, following shareholder approval and regulatory clearance obtained on March 19, 2026. The closing is subject to remaining conditions and customary risks.
Health care again among the state’s biggest M&A deals of the past year
For the third consecutive year, a healthcare-focused company deal is among Wisconsin's largest mergers and acquisitions. Exact Sciences, based in Madison, was acquired by Illinois-based Abbott Laboratories for $21 billion in November. This acquisition follows other significant healthcare M&A deals in the state and notable acquisitions by Modine and several other Wisconsin-based companies across various sectors.
EXACT Sciences Corp. Hits New 52-Week High at $104.00
EXACT Sciences Corp. (EXAS) has achieved a new 52-week high of $104.00, marking a significant 142.34% appreciation over the past year, far outpacing the S&P 500. The company, a mid-cap player in pharmaceuticals and biotechnology with a market capitalization of $19.8 billion, shows a manageable debt-to-equity ratio despite being a loss-making entity with a negative return on equity. This price movement highlights strong investor sentiment and dynamic market activity for the stock.
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
Exact Sciences Corp. announced it will present new data on molecular residual disease (MRD) testing and multi-cancer early detection (MCED) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight findings from the Oncodetect® test in triple-negative breast cancer and updated performance for the Cancerguard® test, reinforcing the company's strategy to detect cancer earlier and monitor disease post-treatment. These results showcase advancements in both tumor-informed ctDNA analysis and multi-biomarker detection approaches for improved cancer care.
EXACT Sciences Corp. Hits New 52-Week High at $103.92
EXACT Sciences Corp. reached a new 52-week high of $103.92, demonstrating strong performance in the Pharmaceuticals & Biotechnology sector with a 142.13% stock price increase over the last year. Despite being a loss-making entity, the company maintains a manageable debt-to-equity ratio of 0.58 and a market capitalization of approximately $19.74 billion, with investors focusing on capital appreciation due to no dividend yield.
Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval
This article reports on the merger between Exact Sciences (EXAS) and Abbott (ABT) moving forward after Exact Sciences shareholders approved the deal. The acquisition will allow Exact Sciences to expand its cancer diagnostic products into new markets and leverage Abbott's global presence. The approval marks a significant step towards the completion of the merger.
Jain Global LLC Purchases Shares of 481,607 Exact Sciences Corporation $EXAS
Jain Global LLC has acquired a significant new position in Exact Sciences (NASDAQ:EXAS), purchasing 481,607 shares valued at approximately $26.35 million. Other institutional investors like Holocene Advisors and Fred Alger Management also increased their stakes, bringing total institutional ownership to about 88.82%. Despite the increased institutional interest, analysts maintain a cautious outlook, with an average "Reduce" rating and a consensus target price of $92.13, even as the stock trades near its 12-month high after a recent EPS miss.
Exact Sciences Corp Stock (ISIN: US30063P1057) Attracts Major Investors Amid Cancer Screening Moment
Exact Sciences Corp. (EXAS) is attracting significant institutional investment, with firms like Bamco Inc. NY increasing their stakes, signaling strong confidence in its colorectal cancer screening leadership. Despite broader healthcare sector pressures and economic uncertainties, investors are drawn to the company's growth trajectory, its flagship Cologuard test, and its potential in preventive oncology, positioning EXAS for a potential rebound. European and DACH region investors are also showing interest due to the company's strong fundamentals and the global demand for accessible cancer screening solutions.
Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp.
EFG Asset Management Americas Corp. significantly increased its stake in Exact Sciences (NASDAQ:EXAS) by 60% in Q3, acquiring 13,910 additional shares, bringing its total to 37,109 shares valued at approximately $2.03 million. This increase in institutional ownership comes despite several analysts recently downgrading EXAS to "Hold" or "Neutral," with an average "Reduce" rating and a target price of $92.13. The company also missed quarterly EPS expectations, reporting $(0.21) against a $0.08 estimate, though it did see a 23.1% revenue growth.
Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval
The article reports that the proposed merger between Exact Sciences (EXAS) and Abbott is progressing well, following key approval from shareholders. This development signifies a major step towards the completion of the acquisition, indicating that the deal is on track to close as planned.
Privia Health Screening Program Increases Colorectal Cancer Screening Rates
Privia Health, in collaboration with Amalgam Rx Inc. and Exact Sciences Corp., successfully increased colorectal cancer screening rates to 84% in 2024 through a program integrating electronic health record workflows and automated patient outreach. The initiative, which utilized Exact Sciences’ Cologuard test, engaged over 100,000 patients nationally and identified more than 550 individuals requiring diagnostic follow-up. This program demonstrates the effectiveness of technology in proactive prevention while reducing administrative burdens for healthcare providers.
Mackenzie Financial Corp Has $150.11 Million Stake in Exact Sciences Corporation $EXAS
Mackenzie Financial Corp recently decreased its stake in Exact Sciences Corporation by 3.9%, now holding 2,743,819 shares valued at $150.11 million. Several other institutional investors have also adjusted their holdings. Analysts currently have a "Reduce" consensus rating for Exact Sciences, with an average target price of $92.13, despite the company missing its last quarterly EPS estimates while revenue grew by 23.1%.
Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate
Exact Sciences, in collaboration with Amalgam Rx and Privia Health, launched a nationwide EHR-enabled outreach program for colorectal cancer screening using its Cologuard test. This initiative has shown improved screening rates and reduced staff workload by automating patient processes. The article highlights how this integration into large-scale healthcare workflows could drive Cologuard adoption, but notes that Exact Sciences still faces significant execution risk due to its high P/E ratio and recent net income loss.
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover
Exact Sciences stock declined premarket despite William Blair's assertion that a potential Abbott Laboratories takeover would likely require a share price exceeding $100. This comes as Abbott is reportedly exploring a major acquisition to expand its diagnostics business, and William Blair maintained "Outperform" ratings on both companies. Exact Sciences' Cologuard is a key asset, and Stocktwits users are pushing for a higher bidding war, suggesting a price of $25-30 billion.
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
Amalgam Rx, Privia Health, and Exact Sciences Corp. announced a successful colorectal cancer (CRC) screening program that achieved an 84% screening rate, surpassing national benchmarks. This program, which uses EHR-integrated workflows and proactive patient outreach with Exact Sciences’ Cologuard test, highlights the importance of scalable, data-driven approaches in closing screening gaps. The initiative engaged over 42,000 patients, processed 23,000 screening orders, and identified more than 550 patients needing diagnostic follow-up, demonstrating a significant impact on preventive care.
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Exact Sciences has been recognized with the Gallup Exceptional Workplace Award for the third consecutive year, a testament to its strong and engaging workplace culture. This award highlights the company's commitment to employee wellbeing, development, and a purpose-driven environment, contributing to its continued success and positive impact on cancer care. Their consistent recognition underscores a sustained effort to foster high employee engagement and a supportive professional atmosphere.
Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld
Exact Sciences' EVP of Human Resources, Sarah Condella, exercised 3,900 stock options at $5.03 per share. To cover tax obligations, 1,913 shares were withheld by Exact Sciences at a value of $103.38 per share. Following these transactions, Condella now directly holds 131,121 shares and indirectly holds 6,368 shares in a 401(k) plan, with additional vested and unvested options and RSUs.
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
This article compares CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS) to determine which offers better value. Utilizing Zacks Rank and Style Scores, it concludes that CSLLY is the superior value option due to its #2 (Buy) Zacks Rank, improving earnings outlook, and more favorable valuation metrics like P/E, PEG, and P/B ratios compared to EXAS.
Why Gallup keeps honoring this cancer test maker’s workplace
Exact Sciences Corp. has received the 2026 Gallup Exceptional Workplace Award for the third consecutive year, recognizing its highly engaged workplace culture. The company is honored for valuing employees and connecting them to its mission of fighting cancer, leading to strong performance. Gallup's research indicates that engaged organizations like Exact Sciences show improved customer ratings, profitability, productivity, and employee well-being.
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum
EXACT SCIENCES CORP (NASDAQ:EXAS) has been identified through a screening method combining technical and fundamental analysis, based on Mark Minervini's SEPA strategy. The company demonstrates strong technical characteristics, including being in a confirmed Stage 2 uptrend with specific moving average arrangements and high relative strength. Fundamentally, EXAS shows robust earnings growth, firm sales, and improving free cash flow, providing a strong basis for its price momentum.
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Exact Sciences has received the Gallup Exceptional Workplace Award (GEWA) for the third consecutive year, recognizing its highly engaged workplace culture. The company, a leading provider of cancer screening and diagnostic tests, was honored for fostering an environment where employees feel valued and connected to its mission, leading to strong performance. This award highlights the company's commitment to its workforce and their role in advancing the fight against cancer.
AI outreach helps engage 100,000 patients on at-home colon cancer screening
Amalgam Rx, Privia Health, and Exact Sciences collaborated on an AI-powered program that significantly increased colorectal cancer screening rates to 84% in 2024 through EHR-enabled patient outreach. The program engaged over 100,000 patients nationally, processed approximately 23,000 screening orders with minimal staff effort, and identified over 550 patients requiring diagnostic follow-up. This initiative highlights the success of scalable, data-driven approaches in closing screening gaps and improving healthcare outcomes.
Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C.
Fox Run Management L.L.C. significantly reduced its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 77.8% in Q3, selling 19,557 shares and retaining 5,581 shares valued at $305,000. Despite a 23.1% year-over-year revenue growth, Exact Sciences missed its EPS estimates, reporting -$0.21 against an expected $0.08. Analysts hold a largely neutral-to-negative outlook on the stock, with 21 "Hold" ratings and 1 "Sell" rating, giving it a consensus "Reduce" rating and an average target price of $92.13.
[Form 4] EXACT SCIENCES CORP Insider Trading Activity
This Form 4 filing reports insider trading activity for Aaron Bloomer, EVP and CFO of Exact Sciences Corp (EXAS). Bloomer received an equity award of 28,063 restricted stock units, which will vest in four equal annual installments starting February 25, 2027. Following this transaction, Bloomer directly holds 48,768 shares of common stock and indirectly holds 417 shares in a 401(k) plan, totaling 49,185 shares, in addition to 32,458 restricted stock units.
EXAS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of Exact Sciences Corp (EXAS), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It highlights the company's financial health signals, including profitability, growth, leverage, liquidity, cash flow, and returns, alongside annual and quarterly data. The report indicates strong revenue growth but notes negative operating and net margins, with mixed earnings quality and concerning interest coverage.
December 18th Options Now Available For EXACT Sciences (EXAS)
New options contracts for EXACT Sciences (EXAS) with a December 18th, 2026 expiration are now available. These contracts offer potential opportunities for premium collection due to the long time until expiration (294 days). Specifically, a covered call strategy using the $105.00 strike price is highlighted, suggesting a potential 1.95% return if the stock is called away.
Exact Sciences stock hits 52-week high at $103.55
Exact Sciences Corporation (EXAS) has hit a new 52-week high of $103.55, bringing its market capitalization to $19.74 billion after a 118% surge over the last six months and 101.85% over the past year. Despite this growth, InvestingPro analysis suggests the stock is currently overvalued. The company's recent merger approval with Abbott Laboratories and new federal legislation for multi-cancer early detection tests are key drivers behind its performance, although some analysts have downgraded the stock to Neutral or Hold.
Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC
The Cologuard multitarget stool DNA (mt-sDNA) test has shown high specificity in screening for colorectal cancer (CRC) among average-risk patients aged 45 to 49 years, offering a noninvasive option. Results published in Cancer Prevention Research indicate a specificity of 95.2% for nonadvanced adenomas and 96.3% for negative colonoscopic findings in this age group. This data supports Cologuard's role as a first-line screening method, particularly following recent guideline changes recommending CRC screenings begin at age 45.
Exact Sciences shareholders approve merger with Abbott Laboratories
Exact Sciences Corp. shareholders have approved the proposed merger with Abbott Laboratories, making Exact Sciences a wholly-owned subsidiary of Abbott. The merger agreement passed with significant shareholder support, although the advisory vote on executive compensation was not approved. The completion of the merger is pending regulatory approvals and other customary closing conditions.
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and increased momentum in cancer testing. The company is exploring blood-based cancer tests and oncology genomics, positioning itself as a key player in early cancer detection in the US. While offering substantial benefits like at-home convenience and broad insurance coverage, the company also faces challenges including competition, high R&D costs, and stock volatility.
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and momentum in cancer diagnostics. The US-focused company is expanding its portfolio into blood-based cancer tests and oncology genomics, aiming to make early detection more accessible. While offering substantial benefits for patients and long-term growth potential for investors, the stock faces volatility from competition, R&D costs, and reimbursement pressures.
